Jonathan Wheeler - CryoCell International Director
| CCEL Stock | USD 8.55 0.10 1.18% |
Director
Dr. Jonathan H. Wheeler M.D., is an Independent Director of the company. Dr. Wheeler is a licensed physician specializing in the fields of obstetrics and gynecology. He has practiced in these fields in Newport Beach, California since 1992. Dr. Wheeler received his B.A. in Biology from the State University of New York at Buffalo. He completed his medical degree at Cornell University Medical College in 1986. His Obstetrics and Gynecology training was received at UCLA Medical Center in a combined internship and residency program. There, he received honorary awards for his work in advanced laparoscopy and completed research in innovative surgical techniques since 2011.
| Age | 55 |
| Tenure | 13 years |
| Professional Marks | Ph.D |
| Address | 700 Brooker Creek Boulevard, Oldsmar, FL, United States, 34677 |
| Phone | 813 749 2100 |
| Web | https://www.cryo-cell.com |
Jonathan Wheeler Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jonathan Wheeler against CryoCell International stock is an integral part of due diligence when investing in CryoCell International. Jonathan Wheeler insider activity provides valuable insight into whether CryoCell International is net buyers or sellers over its current business cycle. Note, CryoCell International insiders must abide by specific rules, including filing SEC forms every time they buy or sell CryoCell International'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jonathan Wheeler few days ago Acquisition by Jonathan Wheeler of 7500 shares of CryoCell International at 3.08 subject to Rule 16b-3 | ||
Jonathan Wheeler over two months ago Acquisition by Jonathan Wheeler of 7500 shares of CryoCell International subject to Rule 16b-3 | ||
Jonathan Wheeler over six months ago CryoCell International exotic insider transaction detected | ||
Jonathan Wheeler over a year ago Acquisition by Jonathan Wheeler of 7500 shares of CryoCell International subject to Rule 16b-3 |
CryoCell International Management Efficiency
Return On Equity is expected to rise to 1.04 this year, although the value of Return On Tangible Assets are projected to rise to (0.14). At this time, CryoCell International's Other Assets are quite stable compared to the past year. Debt To Assets is expected to rise to 0.17 this year, although the value of Net Tangible Assets will most likely fall to (17.6 M). CryoCell International's management efficiency ratios could be used to measure how well CryoCell International manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Ann Blouin | The Ensign Group | 65 | |
| Yongjun Li | Concord Medical Services | N/A | |
| Andrew Adams | National HealthCare | 72 | |
| James Ely | Select Medical Holdings | 63 | |
| Zhang Liping | Concord Medical Services | N/A | |
| Roy Youngblood | P3 Health Partners | N/A | |
| William Grieco | Acadia Healthcare | 64 | |
| William Frist | Select Medical Holdings | 69 | |
| James Seward | Brookdale Senior Living | 65 | |
| Jackie Clegg | Brookdale Senior Living | 56 | |
| Ting Lee | Concord Medical Services | 51 | |
| Kyle Lattner | Acadia Healthcare | 29 | |
| EPerot Bissell | Acadia Healthcare | 58 | |
| Frank Bumstead | Brookdale Senior Living | 78 | |
| Leopold Swergold | Select Medical Holdings | 77 | |
| Bryan Cressey | Select Medical Holdings | 71 | |
| Mark Parrell | Brookdale Senior Living | 49 | |
| Paul Abernathy | National HealthCare | 82 | |
| Russell Carson | Select Medical Holdings | 77 | |
| Enrique Sosa | Mednax Inc | 79 | |
| Daniel Thomas | Select Medical Holdings | 62 | |
Management Performance
| Return On Equity | 1.29 | ||||
| Return On Asset | -0.0093 |
CryoCell International Leadership Team
Elected by the shareholders, the CryoCell International's board of directors comprises two types of representatives: CryoCell International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CryoCell. The board's role is to monitor CryoCell International's management team and ensure that shareholders' interests are well served. CryoCell International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CryoCell International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Portnoy, Co-CEO and Director | ||
| Jill Taymans, CFO and VP of Fin. | ||
| Arthur Ellis, Director | ||
| Brian Sheehy, Director | ||
| Joanne MD, Medical Board | ||
| Oleg Mikulinsky, Chief Officer | ||
| David Portnoy, Chairman and Co-CEO | ||
| George Gaines, Director | ||
| Jonathan Wheeler, Director | ||
| Harold Berger, Director |
CryoCell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CryoCell International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.29 | ||||
| Return On Asset | -0.0093 | ||||
| Profit Margin | (0.31) % | ||||
| Operating Margin | 0.10 % | ||||
| Current Valuation | 78.98 M | ||||
| Shares Outstanding | 8.1 M | ||||
| Shares Owned By Insiders | 47.21 % | ||||
| Shares Owned By Institutions | 10.80 % | ||||
| Number Of Shares Shorted | 9.45 K | ||||
| Price To Earning | 10.76 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CryoCell International in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CryoCell International's short interest history, or implied volatility extrapolated from CryoCell International options trading.
Pair Trading with CryoCell International
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CryoCell International position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CryoCell International will appreciate offsetting losses from the drop in the long position's value.Moving against CryoCell Stock
| 0.84 | ETON | Eton Pharmaceuticals Upward Rally | PairCorr |
| 0.78 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.78 | EVOK | Evoke Pharma | PairCorr |
| 0.78 | EXAI | Exscientia ADR Financial Report 22nd of May 2024 | PairCorr |
| 0.71 | TFX | Teleflex Incorporated Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to CryoCell International could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CryoCell International when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CryoCell International - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CryoCell International to buy it.
The correlation of CryoCell International is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CryoCell International moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CryoCell International moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CryoCell International can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CryoCell International. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.Note that the CryoCell International information on this page should be used as a complementary analysis to other CryoCell International's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for CryoCell Stock analysis
When running CryoCell International's price analysis, check to measure CryoCell International's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CryoCell International is operating at the current time. Most of CryoCell International's value examination focuses on studying past and present price action to predict the probability of CryoCell International's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CryoCell International's price. Additionally, you may evaluate how the addition of CryoCell International to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is CryoCell International's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.25) | Earnings Share (1.16) | Revenue Per Share 3.783 | Quarterly Revenue Growth 0.004 | Return On Assets (0.01) |
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.